Red Flags for Hereditary Cancer related to your Prostate Cancer patient:
Metastatic Prostate Cancer
Prostate cancer patient with a Gleason Score of 7+ AND they have one or more family members with any of the following:
- Breast Cancer ≤ 50 years old
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer with Gleason Score of 7+
Cancer risks for patients with a hereditary cancer syndrome:2
- Breast Cancer Risk up to 68x the general population.
- Prostate Cancer Risk up to 1.5x the general population.
- Pancreatic Cancer Risk up to 7x the general population.
- Increased risk for Melanoma and Colon Cancer
- Breast Cancer Risk up to 11x the general population.
- Ovarian Cancer Risk up to 44x the general population.
- Uterine Cancer Risk up to 47x the general population.
- Increased risk for Melanoma, Pancreatic Cancer and Colon Cancer
Download A Free Risk Assessment Sheet
Evaluate patients with prostate cancer who may be candidates for hereditary cancer testing.
This risk assessment questionnaire can be used to help identify patients with a family history of cancer who may be appropriate for testing.
Myriad myRisk™ Hereditary Cancer is a scientific advancement revolutionizing hereditary cancer testing.
Prostate cancer patients with BRCA mutations are associated with poor survival outcomes and should be considered for tailored clinical management.3
- Poly (ADP-ribose) polymerase (PARP) inhibitors have specific activity in BRCA-associated cancers, including prostate cancer.4
- Mutation carriers may also respond better to platinum-based chemotherapy.4
- Screening for secondary cancers should be included in management.
- NCCN Clinical Practice Guidelines in Oncology Version 2.2015
- For reference and supporting data on the information provided visit www.MyriadPro.com/References
- Castro E, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013 May 10;31(14):1748-57
- Bratt O, et al. Clinical Management of Prostate Cancer in Men with BRCA Mutations. Eur Urol. 2015 Aug;68(2):194-5